advantadesigngroup.com
Public Relations « Advanta Design Group
http://advantadesigngroup.com/public-relations
Building Better Brands - It's in our DNA. Scientific & Abstract Poster Design. News & Media. Download a PDF version of our sevices brochure for a consolidated overview of what we can do for you. Download a PDF version of our current case studies to see what we have done for our respected clients. About 16 hours ago. Lovin' our new marketing materials - folder by @ IPCfolders. Sell sheets by @ Haddonfield dt. S own Express It. Wow! Send link to Friend. Enter below security code. Send to a friend.
oncovirx.advantadna.com
Company Overview - OncoViRxOncoViRx
http://oncovirx.advantadna.com/overview
Research & Development. Our Pipeline – Small Molecule Inhibitors. B, and Notch1 pathways, and anticipate initial clinical development will be in several sub-types of relapsed/refractory non-Hodgkin’s lymphoma and/or acute myeloid leukemia. Two of these compounds, which are in the same class, have been selected for further development, and the Winkler Laboratory is now developing analogs of these compounds. Our goal is to develop novel treatments that are efficacious, have reduced short and long term ...
oncovirx.com
Team -OncoViRx
http://oncovirx.com/team
Research & Development. Our Pipeline – Small Molecule Inhibitors. Dr Erle Robertson, PhD. Dr Erle Robertson is a Professor at the University of Pennsylvania School of Medicine. He holds appointments in the Departments of Microbiology and Radiation Oncology. He is also the director of the Tumor Virology Training Program at the Abramson Cancer Center. Francis Humann, MBA. Mr Humann holds an MBA from Columbia University. Lisa Wisniewski, PhD. Pedram Alaedini, MBA. Senior CMC and Manufacturing Advisor.
oncovirx.com
Our Pipeline - Small Molecule InhibitorsOncoViRx
http://oncovirx.com/small-molecule-inhibitors
Research & Development. Our Pipeline – Small Molecule Inhibitors. OUR PIPELINE - SMALL MOLECULE INHIBITORS. OncoViRx is developing therapeutics to target specific mechanisms of oncogenesis. Specifically, the company is primarily focusing on compounds for inhibition of c-MYC, and NF- K. B, and secondarily Notch1. Within the next 12 months, our plan is to develop a number of additional analogs, complete. Screening, and then advance the most promising candidates into a pilot. Study We anticipate initial cli...
oncovirx.com
Company Overview -OncoViRx
http://oncovirx.com/overview
Research & Development. Our Pipeline – Small Molecule Inhibitors. B, and Notch1 pathways, and anticipate initial clinical development will be in several sub-types of relapsed/refractory non-Hodgkin’s lymphoma and/or acute myeloid leukemia. Two of these compounds, which are in the same class, have been selected for further development, and the Winkler Laboratory is now developing analogs of these compounds. Our goal is to develop novel treatments that are efficacious, have reduced short and long term ...
oncovirx.com
About Blood Cancers -OncoViRx
http://oncovirx.com/about-blood-cancers
Research & Development. Our Pipeline – Small Molecule Inhibitors. Hematologic malignancies are blood cancers that begin in blood forming tissue or cells of the immune system, and include diseases such: as leukemias, lymphomas, and multiple myeloma. While there are variations depending on the specific disease type, incidence rates are fairly consistent among men and women and by ethnicity with incidence rates increasing with age of the population. In the United States:. Lymphoma cells multiply and form tu...
oncovirx.com
News -OncoViRx
http://oncovirx.com/news
Research & Development. Our Pipeline – Small Molecule Inhibitors. January 24, 2017. Money Matters TV 16-46 with Francis Humann. NEWS Money Matters TV 16-46 with Francis Humann. Do you like it? February 24, 2016. Francis Humann Joins OncoViRx As CEO and President. NEWS Francis Humann Joins OncoViRx As CEO and President Francis brings over 17 years of pharmaceutical industry experience at Pfizer, Wyeth, and Abbott in product launch […]. Do you like it? 3401 Grays Ferry Ave. Bldg 212, Suite 136.
